88 related articles for article (PubMed ID: 1979347)
1. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer.
Fendly BM; Kotts C; Vetterlein D; Lewis GD; Winget M; Carver ME; Watson SR; Sarup J; Saks S; Ullrich A
J Biol Response Mod; 1990 Oct; 9(5):449-55. PubMed ID: 1979347
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
3. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
4. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
6. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ
J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829
[TBL] [Abstract][Full Text] [Related]
7. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.
Fendly BM; Winget M; Hudziak RM; Lipari MT; Napier MA; Ullrich A
Cancer Res; 1990 Mar; 50(5):1550-8. PubMed ID: 1689212
[TBL] [Abstract][Full Text] [Related]
8. [Changes in immune function of dendritic cells infected by recombinant adenovirus containing Her2/neu gene of extracellular and transmembrane domain proteins].
Ma SD; Luo RC; Ding ZH; Lu F; Yuan CQ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1184-7. PubMed ID: 16939917
[TBL] [Abstract][Full Text] [Related]
9. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
[TBL] [Abstract][Full Text] [Related]
10. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu antisense targeting of human breast carcinoma.
Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
13. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.
Roh H; Pippin J; Boswell C; Drebin JA
J Surg Res; 1998 Jun; 77(1):85-90. PubMed ID: 9698539
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
Mohanty K; Saha A; Pal S; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Breast Cancer Res Treat; 2007 Jul; 104(1):1-11. PubMed ID: 17004107
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ
Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166
[TBL] [Abstract][Full Text] [Related]
18. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
19. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
[TBL] [Abstract][Full Text] [Related]
20. SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu.
Wen CC; Cheng SA; Hsuen SP; Huang YL; Kuo ZK; Lee HF; Kuo CH; Du JL; Wang WB
Cancer Res; 2006 Jun; 66(11):5847-57. PubMed ID: 16740724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
